N/A N=223 Self-guided Treatment for Adolescents Navigating Depression
Depressive Symptoms · Depression · Depressive Disorder
Primary: Depressive Symptom Severity at Post-intervention — 8.39; 11.03 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=148 Restylane Defyne for Correction of Chin Retrusion
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
N/A N=16 The Cherokee Study: Cherokee Health for Elderly Residents With Osteoarthritis of the Knee
Osteoarthritis
Primary: Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) - Knee Pain — 67.13; 62.04 score on a scale
N/A N=40 Clinical Validation Study for CPM Device
Heart Failure
Primary: Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate — 96.3; 95.7 Percent
N/A N=40 The Peace of Mind and Body Project: Treatment Development of Yoga for Anger Management in Incarcerated Adults
Anger · Aggression
Primary: Program Satisfaction — 29.76; 26.69 score on a scale
Phase 2 N=99 Prospective Study of Rapamycin for the Treatment of SLE
Systemic Lupus Erythematosus (SLE)
Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale
N/A N=119 Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
Nasal Airway Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale - 3 Month Responder Rate — 88.3; 42.5 percentage of participants
Phase 1 N=9 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Sarcoma
Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants
Phase 3 N=1,458 House Dust Mite Allergy Trial In Children
Allergic Rhinitis Due to Dermatophagoides Farinae · Allergic Rhinitis Due to Dermatophagoides Pteronyssinus · Allergic Rhinitis Due to House Dust Mite
Primary: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment Period — 3.4; 4.4 score on a scale — p=<0.0001
Phase 3 N=499 A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Multiple Sclerosis, Relapsing-Remitting
Primary: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 — 0.05; 0.20 number of T2 lesions — p==0.0755
N/A N=41 Respiration Validation for CPM Device
Cardiopulmonary Disease
Primary: Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate — 99.1; 98.5 Percent
N/A N=102 ANI Versus Standard Care in Surgical Patients Receiving Balanced Sevoflurane-Fentanyl Anesthesia
Acute Pain
Primary: The Incidence of Severe Postoperative Pain — 49; 53 Participants
N/A N=83 Caring for Providers to Improve Patient Experience Study Phase 2 in Migori County
Maternal Health · Mental Health · Healthcare Provider
Primary: Change in Perceived Stress Scale (PSS) Score From Baseline to 6 Months — 20.89; 20.58; 18.63; 20.05 score on a scale
N/A N=16 HypErthermia as an Additional Treatment for the Biology and Experience of Depression
Major Depressive Disorder
Primary: Average Number of Planned WBH Sessions Completed — 7.83; 3.20 Count of WBH Sessions